title: Alterations of pancreatic amylase secretion in the reserpinized rat model of cystic fibrosis. Effects of cerulein and EGF.
abstract: Reserpine treatment resulted in altered enzyme secretion from rat pancreatic acini in response to carbamylcholine and secretin (1,2). This study was undertaken: (1) To evaluate if the alterations caused by reserpine can be prevented by EGF and/or cerulein treatments; (2) To determine the time-course of secretion recovery after reserpine treatment; and (3) To establish if EGF and/or cerulein treatments can accelerate such a recovery after the reserpine treatment. Male Sprague-Dawley rats (250-265 g) were used in these experiments. In experiment I, rats divided into three groups received either reserpine (R) or the reserpine vehicle for the controls (C) and the pair-fed controls (PF) for 7 d. During treatment, PF and R rats were given SC, twice a day, saline, EGF (10 micrograms/kg), cerulein (1 microgram/kg), or both at the same dose. C rats received saline in gelatin. In experiment II, rats were treated for 7 d with reserpine or the vehicle as described in experiment I, were allowed a 30-d recovery period and then were killed. In experiment III, C, PF, and R rats were treated for 7 d as described in experiment I; on the 8th d and for the next 6 d, reserpine rats received saline (reserpine-saline), cerulein, EGF, or both cerulein +EGF at the same dose as indicated in experiment I. C and PF rats received saline in gelatin. After sacrifice, acini were prepared, and amylase dose-response curves to carbamylcholine (Cch) and secretin were established. EGF, cerulein, or their combination given to R rats did not improve the desensitized secretory response to Cch.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Département de Biologie, Faculté des Sciences, Université de Sherbrooke, Québec, Canada.
authors.forename: J
authors.initials: J
authors.lastname: Morisset
authors.forename: F L
authors.initials: FL
authors.lastname: Bérubé
authors.forename: M
authors.initials: M
authors.lastname: Vanier
authors.forename: O
authors.initials: O
authors.lastname: Benrezzak
mesh_terms: D000681:Amylases / Q000378:metabolism*; D000818:Animals; D002217:Carbachol / Q000494:pharmacology; D002108:Ceruletide / Q000494:pharmacology; D003550:Cystic Fibrosis / Q000378:metabolism*; D004195:Disease Models, Animal; D004815:Epidermal Growth Factor / Q000494:pharmacology; D008297:Male; D010179:Pancreas / Q000201:enzymology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D012110:Reserpine / Q000494:pharmacology*; D012633:Secretin / Q000494:pharmacology
chemical_list: D012633:Secretin; D004815:Epidermal Growth Factor; D002108:Ceruletide; D012110:Reserpine; D002217:Carbachol; D000681:Amylases